Rivastigmine, the active ingredient of Exelon, is a cholinesterase inhibitor for adults with mild to moderate Alzheimer’s disease or Parkinson’s disease dementia. It supports acetylcholine activity in the brain, which may help maintain memory and thinking for some patients. Exelon capsules require gradual dose adjustment and medical review.
Exelon capsules contain rivastigmine, a medicine from the cholinesterase inhibitor class. Cholinesterase inhibitors slow the breakdown of acetylcholine, a chemical messenger involved in memory, attention and other thinking processes.
Exelon is supplied on this page as capsules for oral use. Capsule strength and pack size are separate facts: the number of capsules in a pack does not describe the amount of rivastigmine in each capsule.
The prescribed strength may change during titration. It is not appropriate to select a higher capsule strength because symptoms appear unchanged after a few days.
Exelon treatment follows a titration pathway rather than a fixed dose for every adult:
The dose is decided individually, taking age, other medicines and health conditions into account. Frailty, low body weight, reduced kidney or liver function, previous stomach ulcers and a slow resting pulse may require closer supervision.
Oral rivastigmine should be increased only according to the prescribed schedule. Nausea during the first days does not always mean the treatment must stop, but repeated vomiting, dehydration or marked weight loss requires prompt medical assessment.
Capsules and transdermal rivastigmine are not interchangeable milligram-for-milligram. A person changing from one formulation to another needs a specific conversion plan rather than an improvised substitution.
Exelon is a prescription treatment. The prescriber decides whether the cognitive and functional response justifies continuation.
A single missed dose usually does not justify taking extra medicine. The next dose should follow the prescribed schedule unless a clinician gives different instructions.
An interruption lasting several days is different. Restarting at the previous maintenance dose can provoke severe gastrointestinal symptoms, so medical guidance is needed before treatment resumes.
Exelon capsules contain rivastigmine, a medicine from the cholinesterase inhibitor class. Cholinesterase inhibitors slow the breakdown of acetylcholine, a chemical messenger involved in memory, attention and other thinking processes. Exelon supports symptoms; it does not reverse established dementia or stop the underlying neurodegenerative disease.
Rivastigmine is authorised for:
The diagnosis must match the licensed indication. Memory lapses caused by poor sleep, depression, vitamin deficiency, thyroid disease or another condition do not automatically justify treatment with Exelon.
The European Medicines Agency describes rivastigmine as a treatment that may improve or stabilise cognitive and functional symptoms in suitable patients [1]. A prescriber usually considers memory performance, daily functioning, other medicines, body weight, heart rate and gastrointestinal health before treatment begins.
Rivastigmine inhibits two enzymes:
The central nervous system, or CNS, includes the brain and spinal cord. In dementia, cholinergic signalling may be impaired, so preserving acetylcholine can support the remaining communication between nerve cells.
Rivastigmine binds to cholinesterase enzymes and slows their activity. Acetylcholine then remains available for longer in parts of the brain involved in attention and memory.
A simplified sequence is:
A neurotransmitter is a chemical messenger used by nerve cells. The effect is supportive rather than restorative: increasing acetylcholine cannot replace neurons already lost through Alzheimer’s disease or Parkinson’s disease dementia.
Rivastigmine addresses selected symptoms within specific diagnosed conditions; it is not a general treatment for every type of memory complaint [2].
Rivastigmine is authorised for:
The diagnosis must match the licensed indication.
One practical point is easy to miss: a family member may need to supervise administration when memory impairment affects adherence. A written medicine schedule can help, but it should not replace a clinical review when doses are repeatedly missed.
Exelon may not be for you if a clinician judges that its risks outweigh its benefits or if you cannot take capsules safely with food.
Rivastigmine most often causes gastrointestinal symptoms during initiation or dose increases. Nausea, vomiting, diarrhoea, reduced appetite, abdominal discomfort and weight loss can occur. Dizziness, headache, tremor, fatigue and increased sweating are also recognised adverse effects.
Persistent vomiting is not an effect to simply tolerate, especially when fluids cannot be kept down. Dehydration can cause weakness, confusion, low blood pressure and kidney stress. Severe gastrointestinal reactions can become dangerous through fluid loss, bleeding or substantial weight loss; fatal outcomes are rare.
Seek urgent medical assessment for:
The MHRA safety information for cholinesterase inhibitors emphasises the importance of recognising bradycardia, syncope and gastrointestinal intolerance in susceptible patients [3].
Transdermal Exelon exists as a separate rivastigmine delivery option, but the product described here is the capsule formulation. A capsule should not be replaced with a patch without a prescriber’s dosing plan.
Patients using transdermal treatment must never apply two patches accidentally. Anyone who discovers that more than the prescribed amount has been applied should remove the excess patch and obtain urgent medical advice, especially if nausea, vomiting, sweating, faintness or confusion develops.
Rivastigmine belongs to the cholinesterase inhibitor group. Other treatment approaches use different mechanisms, so the best option depends on diagnosis, frailty, heart rate, gastrointestinal tolerance, adherence and previous response.
| Treatment approach | Main mechanism and route | Practical considerations |
|---|---|---|
| Rivastigmine capsules | Cholinesterase inhibition; oral administration | Taken with food; nausea, vomiting and weight loss may limit titration |
| Other cholinesterase inhibitors | Cholinesterase inhibition; oral or transdermal options vary | Choice depends on tolerance, dosing routine and clinical history |
| Memantine | NMDA-receptor modulation; oral administration | Used in different dementia stages and clinical contexts; not a direct substitute for rivastigmine |
Donepezil and galantamine are also cholinesterase inhibitors, while memantine acts through a different glutamate-related pathway. No option is universally preferable. A person who struggles with several daily oral medicines may be considered for a transdermal approach, while someone with skin sensitivity may prefer an oral formulation.
A patch is not automatically safer or more effective. It can reduce swallowing difficulties for some people, yet application errors and skin reactions create different risks. Capsules are unsuitable when swallowing is unsafe, but they avoid adhesive-related reactions.
In clinical practice, doctors usually judge Exelon by daily function rather than by memory complaints alone. A patient who remains able to prepare breakfast, hold a conversation or manage familiar tasks may be gaining meaningful support even without a dramatic subjective improvement.
The prescribing clinician also looks for harm. Persistent nausea, falls, fainting, slow pulse, tremor or weight loss can make dose reduction more appropriate than escalation. A stable dose that is tolerated may be preferable to a higher dose that causes repeated interruptions.
The EMA assessment of rivastigmine supports this benefit–tolerability approach [4]. Family observations are valuable because dementia can affect a patient’s ability to recognise changes in memory, appetite or medicine use.
Medicines that reduce heart rate can add to rivastigmine-related bradycardia or fainting risk. The MHRA's 2015 safety advice recommends medication review when cholinesterase inhibitors are used alongside treatments affecting cardiac conduction, including some beta-blockers and other rate-limiting medicines [5]. A prescriber should assess pulse, fainting history and the full medicine list before combining them. Do not stop a heart medicine abruptly without a specific plan.
Rivastigmine is titrated gradually, so the treatment effect is usually assessed over several weeks rather than after one capsule. NHS dementia prescribing practice in 2023 generally reviews cognition, function and adverse effects after dose changes instead of relying on a single day’s impression. Some families notice changes in attention or routine first, while others see little measurable benefit. Absence of an early dramatic improvement does not justify increasing the dose independently.
The prescriber should know about fainting, a slow heartbeat, stomach ulcers, asthma, seizures, Parkinsonian symptoms, kidney disease, liver disease and recent weight loss. The complete list of prescription medicines, over-the-counter products and supplements is also relevant. The EMA product information from 2000 describes these factors because they can alter tolerability or interaction risk. Tell the clinician if swallowing capsules or taking medicine with meals is difficult.
Exelon is used in older adults with diagnosed Alzheimer’s disease or Parkinson’s disease dementia, but age increases the importance of careful titration. Frailty, low body weight, dehydration, falls and several concurrent medicines can make adverse effects more serious. WHO dementia guidance from 2023 supports individual assessment of function, comorbidity and care needs when treatment is selected. A slower increase or a lower maintenance dose may be appropriate for a vulnerable patient.
The best schedule is the one prescribed for the individual, with each capsule taken with food. Many people use breakfast and the evening meal when twice-daily administration has been prescribed, but the exact routine must come from the clinician. The 2024 Electronic Medicines Compendium product information for rivastigmine emphasises administration with food to improve gastrointestinal tolerability. Linking the dose to a regular meal can make missed doses less likely.
Alcohol can worsen dizziness, drowsiness, impaired balance and confusion in a person taking rivastigmine. The MHRA's 2015 safety advice recommends caution with activities affected by these symptoms, especially in older adults who already have a fall risk. Avoid alcohol if it causes unsteadiness, worsens confusion or makes medicine administration unreliable. Anyone experiencing fainting, severe vomiting or marked drowsiness needs medical assessment rather than further alcohol.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Martin, 29 - Exeter, took rivastigmine capsules for a relative and found that taking them with breakfast reduced early nausea. The first week was difficult, and the family needed a written schedule because a missed dose was followed by confusion about whether to repeat it.
Steven, 64 - Luton, had used Exelon for several months under supervision. His family noticed better participation in conversation after the dose was settled, but he developed reduced appetite during an increase and needed a lower dose for a period.
Ben, 69 - Bath, reported that the capsules were manageable when taken with food. He felt dizzy after one dose taken later than usual and became more cautious about standing up quickly, although the treatment did not produce a clear memory improvement for him.
